Development of new microbiota-inspired compounds for the validation of NPM1 protein as a therapeutic target for acute myeloid leukemia
Despite early diagnosis and the development of new treatments, many patients with acute myeloid leukemia (AML) continue to fail therapy, resulting in relapses and more aggressive cancers with poor prognosis. Therefore, the development of new therapies targeting critical genetic mutations affecting A...
| Autor: | |
|---|---|
| Tipo de recurso: | tesis doctoral |
| Fecha de publicación: | 2024 |
| País: | España |
| Institución: | Universidad Complutense de Madrid (UCM) |
| Repositorio: | Docta Complutense |
| Idioma: | inglés |
| OAI Identifier: | oai:docta.ucm.es:20.500.14352/118975 |
| Acceso en línea: | https://hdl.handle.net/20.500.14352/118975 |
| Access Level: | acceso abierto |
| Palabra clave: | 616.155.392-036.11(043.2) Leucemia mieloide aguda Química 23 Química |
| Sumario: | Despite early diagnosis and the development of new treatments, many patients with acute myeloid leukemia (AML) continue to fail therapy, resulting in relapses and more aggressive cancers with poor prognosis. Therefore, the development of new therapies targeting critical genetic mutations affecting AML patients is of great importance to achieve effective treatments. In this regard, mutations in the nucleophosmine 1 gene (NPM1mut) represent the most common genetic alteration found in AML patients... |
|---|